Linezolid, 98%

Name: Linezolid, 98%
SKU: 460592500

Linezolid, Zyvox, CAS # 165800-03-3 is a synthetic oxazolidinone antibiotic. | CAS: 165800-03-3 | C₁₆H₂₀FN₃O₄ | 337.35 g/mol

テクニカルサポートオーダーサポート

表示を変更

数量:

250 mg

1 g

Chem dex^TM Webアプリをお試しください

製品番号（カタログ番号） 460592500

価格（JPY）

見積もりを依頼する

数量:

250 mg

一括またはカスタム形式をリクエストする

化学物質識別子

CAS165800-03-3

IUPAC NameN-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide

Molecular FormulaC16H20FN3O4

InChI KeyTYZROVQLWOKYKF-ZDUSSCGKSA-N

SMILESCC(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(N2CCOCC2)C(F)=C1

さらに表示

仕様

スペックシート

Appearance (Form)Powder

HPLC>=97.5 %

Loss on drying=<0.5 %

Infrared spectrumConforms

Appearance (Color)White to off-white

This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

• Linezolid is an organoflourine compound and an acetamide

• Linezolid acts by inhibiting initiation complex formation by binding to the 50S ribosomal subunit

Applications

• Linezolid is effective against staphylococcal and enterococcal microbes

• It is most effective against gram-positive organisms, particularly methicillin, vancomycin and penicillin resistant ones

• Suitable for research on antibiotic resistance, cross-reactivity and drug mechanisms

RUO – Research Use Only

General References:

Conradie, F.; Diacon, A.H.; Ngubane, N.; Howell, P.; Everitt, D.; Crook, A.M.; Mendel, C.M.; Egizi, E.; Moreira, J.; Timm, J.; McHugh, T.D.; Wills, G.H.; Bateson, A.; Hunt, R.; Van Niekerk, C.; Li, M.; Olugbosi, M.; Spigelman, M. Nix-TB Trial Team. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020, 382(10), 893-902.
Willekens, R.; Puig-Asensio, M.; Ruiz-Camps, I.; Larrosa, M.N.; González-López, J.J.; Rodríguez-Pardo, D.; Fernández-Hidalgo, N.; Pigrau, C.; Almirante, B. Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study. Clin Infect Dis. 2019, 69(3), 381-387.